Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2014

01-05-2014 | Short Communication

Efficacy and safety of oral low-dose glucocorticoids in patients with estrogen-dependent primary osteoarthritis

Authors: Carlos A. Cañas, Carlos J. Osorio, Nicolás Coronel, Magda C. Cepeda, Jorge H. Izquierdo, Fabio Bonilla-Abadía

Published in: Rheumatology International | Issue 5/2014

Login to get access

Abstract

Estrogen-dependent osteoarthritis (EDPOA) is a disease of perimenopausal-age women. Their manifestations are polyarticular pain with common co-morbidities (carpal tunnel syndrome, insomnia, fatigue, depression, and fibromyalgia). Based on dual role of glucocorticoids, its trophic action on the chondrocyte and its anti-inflammatory effect, we conducted a prospective interventional cohort study where we evaluate the efficacy and safety of oral low-dose GC in one hundred women with EDPOA. The pain intensity, number of tender joints as well as impact in co-morbidities were analyzed. We conclude that the use of low-dose GC in patients with EDPOA can be an effective and a safe therapeutic option.
Literature
1.
Elders MJ (2000) The increasing impact of arthritis on public health. J Rheumatol Suppl 60:6–8PubMed
2.
Brandt KD, Dieppe P, Radin EL (2008) Etiopathogenesis of osteoarthritis. Rheum Dis Clin N Am 34:531–559CrossRef
3.
Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR (2011) Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ 14:497–507PubMed
4.
Bijlsma JWJ, Berenbaum F, Lafeber FPJG (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377:2115–2126PubMedCrossRef
5.
Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA (2009) Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 39:71–80PubMedCrossRef
6.
7.
Madsen SH, Andreassen KV, Christensen ST, Karsdal MA, Sverdrup FM, Bay-Jensen AC, Henriksen K (2011) Glucocorticoids exert context-dependent effects on cells of the joint in vitro. Steroids 76(13):1474–1482PubMedCrossRef
8.
Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D et al (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33:1601–1610PubMedCrossRef
9.
Altman R, Asch E, Bloch D, Bole G, Borenstein D et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:1039–1049PubMedCrossRef
10.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C et al (1990) The American College of Rheumatology 1990 Criteria for the classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Reum 33:160–172CrossRef
11.
Richardson DW, Dodge GR (2003) Dose-dependent effects of corticosteroids on the expression of matrix-related genes in normal and cytokine-treated articular chondrocytes. Inflamm Res 52:39–49PubMedCrossRef
12.
Derfoul A, Perkins GL, Hall DJ, Tuan RS (2006) Glucocorticoids promote chondrogenic differentiation of adult human mesenchymal stem cells by enhancing expression of cartilage extracellular matrix genes. Stem Cells 24:1487–1495PubMedCrossRef
13.
Cvoro A, Yuan C, Paruthiyil S, Miller OH, Yamamoto KR, Leitman DC (2011) Crosstalk between glucocorticoid and estrogen receptors occurs at a subset of proinflammatory genes. J Immunol 186:4354–4360PubMedCrossRef
14.
Evans CH, Grodzinsky AJ (2011) Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines. Arthritis Res Ther 13:R142PubMedCentralPubMedCrossRef
15.
Young L, Katrib A, Cuello C, Vollmer-Conna U, Bertouch JV et al (2001) Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study. Arthritis Rheum 44:343–350PubMedCrossRef
Metadata
Title
Efficacy and safety of oral low-dose glucocorticoids in patients with estrogen-dependent primary osteoarthritis
Authors
Carlos A. Cañas
Carlos J. Osorio
Nicolás Coronel
Magda C. Cepeda
Jorge H. Izquierdo
Fabio Bonilla-Abadía
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2603-1

Other articles of this Issue 5/2014

Rheumatology International 5/2014 Go to the issue

Original Article

A randomized placebo-controlled clinical trial of phonophoresis for the treatment of chronic neck pain

Short Communication

Sexual maturation in Moroccan patients with juvenile idiopathic arthritis

Letter to the Editors

MicroRNA-323-3p: a new biomarker and potential therapeutic target for rheumatoid arthritis

Original Article

Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis

Original Article

Unexpected association between joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type and obsessive–compulsive personality disorder

Short Communication

Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits